Exhibit
10.13


 


THERAPIX


BIOSCIENCES


 


Date:
______


To


Mrs./Mr.


 


Letter
of Exculpation 


 


The
Company’s remuneration committee and the board of directors resolved on ______ and the Company’s general meeting with
the requisite legal majority resolved on _____ to grant you this Letter of Exculpation in the form acceptable in the Company with
respect to Officeholders, all as set forth in this Letter of Exculpation, which exempts you from any or all liability towards
the Company for any damage arising from a breach of the duty of care owing to the Company (hereinafter: “the
Exculpation Resolution”), excluding damage resulting from a director’s breach of the duty of care in distribution,
as such term is defined in the Companies Law, 5759-1999. Therefore, we hereby inform you that as you are currently serving and/or
have been serving and/or may be serving in the future as an Officeholder in the Company and/or any of its subsidiaries and/or
affiliates and/or currently employed and/or were employed and/or may be employed in the future by the Company and/or any of its
subsidiaries and/or affiliates, the Company hereby acknowledges and undertakes towards you, subject to the provisions of any law,
as follows:


 


Subject
to the provisions of Sections 259 and 263 of the Companies Law, 5759-1999 and any other statutory provisions in substitution thereto,
the Company hereby exempts you in advance from any liability towards the Company due to any damage, directly or indirectly, sustained
or to be sustained by it due to the breach of the duty of care you owe to the Company, as a result of your acts in good faith
and by virtue of your employment or service as an Officeholder in the Company and/or any of its subsidiaries and/or affiliates,
as applicable, from time to time, excluding a breach of the duty of care in distribution.


 


The
Company’s undertakings under this Letter of Exculpation shall be broadly interpreted and in a manner intending to uphold
them and comply, to the extent permitted under the law, with the purposes of this Letter of Exculpation. In the event of a conflict
between any provision in this Letter of Exculpation and the provisions of any law which cannot be stipulated against, or which
may not be amended or supplemented, such provision of the law shall prevail, but without derogating from and/or prejudicing the
validity and effect of the other provisions of this Letter of Exculpation.


 


Nothing
in this Letter of Exculpation shall be interpreted as derogating from any of the provisions of the Letter of Indemnity granted
to you by the Company, if any.


 


	“Act”
    or anything deriving therefrom for the purpose of this Letter of Exculpation	-	as
    such term is defined in the Companies Law, 5759-1999, including a resolution and/or omission, and including all your acts
    performed by you prior to the date of this Letter of Exculpation during the terms of your employment and/or service as an
    Officeholder in the Company and/or during your service as an Officeholder, employee or agent of the Company for another corporation
    in which the Company directly and/or indirectly holds securities.
	 	 	 
	“Officeholder“
    for the purpose of this Letter of Exculpation	-	as
    such term is defined in the Companies Law, 5759- 1999, including any employee to whom the Company resolves to grant a Letter
    of Indemnity.


 


	 	 
	 	Therapix
    Biosciences Ltd.


 






    


    


    




 


Schedule to Exhibit 10.13


 


The following directors and executive
officers are parties to Exculpation Agreements with the Company which are substantially identical in all material respects to the
representative Exculpation Agreement filed herewith and are dated as of the respective dates listed below. The other Exculpation
Agreements are omitted pursuant to Instruction 2 to Item 601 of Regulation S-K.


 


	Name of Signatory	 	Date
	 	 	 
	Dr. Ascher Shmulewitz	 	February 24, 2016
	Chairman of the Board of Directors	 	 
	 	 	 
	Dr. Elran Haber	 	November 29, 2015
	Chief Executive Officer	 	 
	 	 	 
	Guy Goldin	 	November 29, 2015
	Chief Financial Officer	 	 
	 	 	 
	Doron Ben Ami	 	February 24, 2016
	Chief Strategy Officer	 	 
	 	 	 
	Dr. Adi Zuloff-Shani	 	February 24, 2016
	Chief Technologies Officer	 	 
	 	 	 
	Amit Berger	 	February 24, 2016
	Director	 	 
	 	 	 
	Abraham (Avi) Meizler	 	February 24, 2016
	Director	 	 
	 	 	 
	Dr. Yafit Stark	 	February 24, 2016
	Director	 	 
	 	 	 
	Micha Jesselson	 	February 24, 2016
	Director	 	 
	 	 	 
	Zohar Heiblum	 	February 24, 2016
	Director